Zhongping Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhongping Xie has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Hua Li
Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), 935 Jiao Ling Road, Kunming, Yunnan 650118, China
11 shared publicationsTianhong Xie
Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), 935 Jiao Ling Road, Kunming, Yunnan 650118, China
11 shared publicationsTing Yang
Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), 935 Jiao Ling Road, Kunming, Yunnan 650118, China
11 shared publicationsLei Yue
Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), 935 Jiao Ling Road, Kunming, Yunnan 650118, China
8 shared publicationsXia Song
Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), 935 Jiao Ling Road, Kunming, Yunnan 650118, China
7 shared publications- Lei Yue
Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, 935 Jiao Ling Road, Kunming 650118, China
5 shared publications
Latest Publications
- 29 October 2025
- Vol. 42 (2) , 501-514
[Research progress in the structural design of virus-like particle vaccines].
Virus-like particles (VLPs), nanomaterials without viral genomes and structurally highly similar to natural virus particles, have shown extensive application prospects in vaccine research and biomedicine in recent years. This article systematically summarizes the five core structural characteristics (self-assembly, repetitive and ordered surface structures, clear size range, conformation-dependent epitope presentation, and structural dynamics and plasticity) of VLPs. Then, it analyzes the supporting roles of these characteristics in the immune activation process and targeted functional delivery. On this basis, the review further explores the current optimization strategies for the design of VLPs, including structural simulation, precise modification, and functional enhancement, and summarizes the latest research results to envision the development directions of VLPs in personalized vaccine development, tumor immunotherapy, and intelligent delivery systems. This review aims to provide theoretical references and technical inspirations for the rational design and efficient application of VLPs as platforms.
- 29 October 2025
- Vol. 42 (2) , 501-514
[Research progress in the structural design of virus-like particle vaccines].
Virus-like particles (VLPs), nanomaterials without viral genomes and structurally highly similar to natural virus particles, have shown extensive application prospects in vaccine research and biomedicine in recent years. This article systematically summarizes the five core structural characteristics (self-assembly, repetitive and ordered surface structures, clear size range, conformation-dependent epitope presentation, and structural dynamics and plasticity) of VLPs. Then, it analyzes the supporting roles of these characteristics in the immune activation process and targeted functional delivery. On this basis, the review further explores the current optimization strategies for the design of VLPs, including structural simulation, precise modification, and functional enhancement, and summarizes the latest research results to envision the development directions of VLPs in personalized vaccine development, tumor immunotherapy, and intelligent delivery systems. This review aims to provide theoretical references and technical inspirations for the rational design and efficient application of VLPs as platforms.
- Open Access
- 7 July 2022
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 7 (1) , 1-3
Rapidly developable therapeutic-grade equine immunoglobulin against the SARS-CoV-2 infection in rhesus macaques
- 7 July 2022
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 7 (1) , 1-3
Open AccessRapidly developable therapeutic-grade equine immunoglobulin against the SARS-CoV-2 infection in rhesus macaques
- Open Access
- 1 November 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 143, 112212
Proliferation characteristics of coxsackievirus A10 in mice and immune protection ability of experimental inactivated vaccine
- 1 November 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 143, 112212
Open AccessProliferation characteristics of coxsackievirus A10 in mice and immune protection ability of experimental inactivated vaccine
- Open Access
- 22 September 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (1) , 35-38
A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS‐CoV‐2 vaccine
- 22 September 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (1) , 35-38
Open AccessA third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS‐CoV‐2 vaccine
- Open Access
Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 10 (1) , 2125-2127
Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
Since the initial outbreak in late 2019, coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has evolved into a global pa...
- 1 January 2021
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 10 (1) , 2125-2127
Open AccessAntibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
Since the initial outbreak in late 2019, coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has evolved into a global pa...
- Open Access
- 1 December 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 533 (3) , 296-303
PTP1B negatively regulates STAT1-independent Pseudomonas aeruginosa killing by macrophages
- 1 December 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 533 (3) , 296-303
Open AccessPTP1B negatively regulates STAT1-independent Pseudomonas aeruginosa killing by macrophages
- Open Access
- 23 September 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (3) , 1732-1738
N‐terminally truncated nucleocapsid protein of SARS‐CoV‐2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS‐CoV‐2
The coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) had led to a serious public health crisis, and no specific treatments or vaccines are available yet. A nucleocapsid protein (NP)‐based enzyme‐linked immunosorbent assay (ELISA) detection method is not only important in disease diagnosis, but is required for the evaluation of vaccine efficacy during the development of an inactivated SARS‐CoV‐2 vaccine. In this study, we expressed both the NP and N‐terminally truncated NP (ΔN‐NP) of SARS‐CoV‐2 in an Escherichia coli expression system and described the purification of the soluble recombinant NP and ΔN‐NP in details. The identities of the NP and ΔN‐NP were confirmed with mass spectrometry. We then used immunoglobulin G detection ELISAs to compare the sensitivity of NP and ΔN‐NP in detecting anti‐SARS‐CoV‐2 antibodies. ΔN‐NP showed greater sensitivity than NP in the analysis of serially diluted sera from mice and rabbits vaccinated with inactive SARS‐CoV‐2 and in human sera diluted 1:400. ΔN‐NP showed a positive detection rate similar to that of the SARS‐CoV‐2 S protein in human sera. We conclude that ΔN‐NP is a better serological marker than NP for evaluating the immunogenicity of inactivated SARS‐CoV‐2.
- 23 September 2020
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (3) , 1732-1738
Open AccessN‐terminally truncated nucleocapsid protein of SARS‐CoV‐2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS‐CoV‐2
The coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) had led to a serious public health crisis, and no specific treatments or vaccines are available yet. A nucleocapsid protein (NP)‐based enzyme‐linked immunosorbent assay (ELISA) detection method is not only important in disease diagnosis, but is required for the evaluation of vaccine efficacy during the development of an inactivated SARS‐CoV‐2 vaccine. In this study, we expressed both the NP and N‐terminally truncated NP (ΔN‐NP) of SARS‐CoV‐2 in an Escherichia coli expression system and described the purification of the soluble recombinant NP and ΔN‐NP in details. The identities of the NP and ΔN‐NP were confirmed with mass spectrometry. We then used immunoglobulin G detection ELISAs to compare the sensitivity of NP and ΔN‐NP in detecting anti‐SARS‐CoV‐2 antibodies. ΔN‐NP showed greater sensitivity than NP in the analysis of serially diluted sera from mice and rabbits vaccinated with inactive SARS‐CoV‐2 and in human sera diluted 1:400. ΔN‐NP showed a positive detection rate similar to that of the SARS‐CoV‐2 S protein in human sera. We conclude that ΔN‐NP is a better serological marker than NP for evaluating the immunogenicity of inactivated SARS‐CoV‐2.
- 11 March 2020
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 16 (7) , 1586-1594
Safety and immunogenicity of an experimental live combination vaccine against enterovirus 71 and coxsackievirus A16 in rhesus monkeys
Enterovirus 71 (EV-A71) and Coxsackievirus A16 (CV-A16) are the two most common pathogens causing hand, foot, and mouth disease (HFMD). Previously, we obtained one candidate live attenuated strain each for EV-A71 and CV-A16; here, we evaluated the safety and immunogenicity of a combinedlive vaccine against EV-A71 and CV-A16 generated from these two candidate strains. Rhesus monkeys were intramuscularly treated with a live combinationvaccine against both EV-A71 and CV-A16 or with either vaccine alone. No fever or atypical clinical signs were observed in any animals. Monkeys vaccinated with the combinationlive vaccine presented no notable pathological changes in the brain, spinal cord, lung, and liver; in contrast, these regions showed inflammatory cell infiltration in monkeys treated with EV-A71 alone or CV-A16 alone. Weak viremia was detected in plasma after inoculation with the combinationvaccine; however, the duration of viral shedding in feces was increased. Biochemical studies revealed a slight increase in aspartate aminotransferase levels in monkeys inoculated with the live combination vaccine; however, histopathological findings did not attribute this change to liver damage. We also found that the live combinationvaccine induced a dual humoral immune response. Cytokine analysis indicated that the combined EV-A71/CV-A16 vaccine significantly down-regulated interleukin-8 production. Here, we have demonstrated that the live attenuated EV-A71/CV-A16 vaccine was safe and could trigger a dual specific immune response. However, its immune protection efficacy requires further investigation.
- 11 March 2020
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 16 (7) , 1586-1594
Safety and immunogenicity of an experimental live combination vaccine against enterovirus 71 and coxsackievirus A16 in rhesus monkeys
Enterovirus 71 (EV-A71) and Coxsackievirus A16 (CV-A16) are the two most common pathogens causing hand, foot, and mouth disease (HFMD). Previously, we obtained one candidate live attenuated strain each for EV-A71 and CV-A16; here, we evaluated the safety and immunogenicity of a combinedlive vaccine against EV-A71 and CV-A16 generated from these two candidate strains. Rhesus monkeys were intramuscularly treated with a live combinationvaccine against both EV-A71 and CV-A16 or with either vaccine alone. No fever or atypical clinical signs were observed in any animals. Monkeys vaccinated with the combinationlive vaccine presented no notable pathological changes in the brain, spinal cord, lung, and liver; in contrast, these regions showed inflammatory cell infiltration in monkeys treated with EV-A71 alone or CV-A16 alone. Weak viremia was detected in plasma after inoculation with the combinationvaccine; however, the duration of viral shedding in feces was increased. Biochemical studies revealed a slight increase in aspartate aminotransferase levels in monkeys inoculated with the live combination vaccine; however, histopathological findings did not attribute this change to liver damage. We also found that the live combinationvaccine induced a dual humoral immune response. Cytokine analysis indicated that the combined EV-A71/CV-A16 vaccine significantly down-regulated interleukin-8 production. Here, we have demonstrated that the live attenuated EV-A71/CV-A16 vaccine was safe and could trigger a dual specific immune response. However, its immune protection efficacy requires further investigation.